Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom

Martina Recalde, Elena Roel, Andrea Pistillo, Anthony G. Sena, Albert Prats‐Uribe, Waheed‐Ul‐Rahman Ahmed, Heba Alghoul, Thamir M. Alshammari, Osaid Alser, Carlos Areia, Edward Burn, Paula Casajust, Dalia Dawoud, Scott L. DuVall, Thomas Falconer, Sergio Fernández‐Bertolín, Asieh Golozar, Mengchun Gong, Lana Yin Hui Lai, Jennifer C. E. Lane, Kristine E. Lynch, Michael E. Matheny, Paras Mehta, Daniel R. Morales, Karthik Natarjan, Fredrik Nyberg, Jose Posada, Christian Reich, Lisa M. Schilling, Karishma Shah, Nigam H. Shah, Vignesh Subbian, Lin Zhang, Hong Zhu, Patrick Ryan, Daniel Prieto‐Alhambra, Kristin Kostka, Talita Duarte‐SallesmedRxiv 2020 · DOI

Abstract

Background: COVID-19 may differentially impact people with obesity. This study aimed to describe and compare the demographics, comorbidities, and outcomes of obese patients with COVID-19 to those of non-obese patients, as well as to obese patients with seasonal influenza.

Methods: A multinational cohort study was conducted using outpatient, inpatient, and claims data from January to June 2020 across the United States, Spain, and the United Kingdom. Six databases standardized to the OMOP Common Data Model were utilized. The study followed 627,044 COVID-19 patients and 4,549,568 influenza patients (2017-2018) from the index date to 30 days or death.

Findings: Obesity prevalence was higher among hospitalized COVID-19 patients (38% to 54%) than those with influenza (27% to 48%). Obese COVID-19 patients were more likely to be female and younger than non-obese COVID-19 patients. They also faced higher risks of cardiovascular and respiratory events, intensive care requirements, and mortality compared to both non-obese COVID-19 patients and obese influenza patients.

Interpretation: Obesity is a significant driver of COVID-19 severity. These findings are instrumental for guiding preventive strategies and clinical management for high-risk populations.

Introduction

Early in the COVID-19 pandemic, clinical observations suggested that obesity might be a significant risk factor for poor outcomes. However, early data were often limited to small, single-center studies or lacked a standardized methodology to compare results across different healthcare systems. Furthermore, while COVID-19 was frequently compared to seasonal influenza, there was a lack of large-scale evidence determining if the "obesity penalty" was unique to SARS-CoV-2 or a general trend for viral respiratory infections.

This study addresses these gaps by providing a massive, standardized, and international characterization of how obesity impacts COVID-19 clinical pathways, leveraging data from over 600,000 patients across three countries.

Methodology and Data Standardization

The study utilized a federated analysis approach through the OMOP Common Data Model (CDM). This technical framework allowed researchers to execute a single set of analytical code locally on different databases. This method preserves patient privacy—as raw data never leaves its home institution—while ensuring results are perfectly comparable across international borders.

The researchers defined two main cohorts:

  1. Diagnosed: Patients with a clinical diagnosis or positive test.
  2. Hospitalized: Patients admitted with a COVID-19 diagnosis.

To provide context, "mirror" cohorts of patients with seasonal influenza from the 2017-2018 season were created to serve as a baseline. Obesity was defined through a combination of ICD codes, BMI measurements (≥ 30 kg/m²), or body weight records (≥ 120 kg).

Datasets

The study drew from six major databases:

  • United Kingdom: Clinical Practice Research Datalink (CPRD).
  • Spain: Information System for Research in Primary Care (SIDIAP), covering 80% of the population in Catalonia.
  • United States: Stanford Medicine Research Data Repository (STARR-OMOP), Columbia University Irving Medical Center (CUIMC), IQVIA Open Claims, and the Department of Veterans Affairs (VA-OMOP).

Key Insights

The Obesity Prevalence Gap

One of the most striking findings was that obesity was far more common among hospitalized COVID-19 patients (38% to 54%) than among hospitalized influenza patients (27% to 48%). This suggests that SARS-CoV-2 may have a specific biological synergy with adipose tissue or the proinflammatory state associated with obesity, making infected individuals more likely to require acute care.

Demographic Shifts

Unlike the general trend where COVID-19 severity tracks primarily with advanced age and male sex, obese hospitalized patients were consistently younger and more likely to be female than non-obese patients. This shift suggests that obesity may "offset" the relative protection typically seen in younger, female populations.

Clinical Outcomes and the "Obesity Penalty"

Obese COVID-19 patients faced significantly worse outcomes than their non-obese counterparts and obese influenza patients:

  • Hospitalization Risk: In the IQVIA database, 32% of obese COVID-19 patients required hospitalization compared to 26% of non-obese patients.
  • Intensive Services: Obese patients required ventilation or ICU admission much more frequently. In the VA database, 22% of obese patients required intensive services versus 15% of non-obese patients.
  • Respiratory Distress: Acute Respiratory Distress Syndrome (ARDS) was the most frequent adverse event, occurring in 15% to 46% of obese hospitalized patients.
  • Fatality Rates: While fatality rates between obese and non-obese hospitalized COVID-19 patients were often similar (14-20%), the fatality rate for obese COVID-19 patients was drastically higher than for obese influenza patients (e.g., 12% vs. <3% in some cohorts), despite the influenza patients often having a higher burden of other chronic conditions.

Discussion

The authors hypothesize that the proinflammatory state of obesity, characterized by higher levels of cytokines like interleukin-6 and TNF-alpha, may prime the immune system for the "cytokine storm" observed in severe COVID-19 cases. Additionally, the expression of ACE2 (the entry point for SARS-CoV-2) in adipose tissue may turn fat cells into a viral reservoir.

Limitations

As a descriptive study, it characterizes the cohorts without using complex causal modeling to adjust for every possible confounder. Furthermore, obesity is often under-recorded in electronic health records (EHRs), meaning the true prevalence and impact might be even higher than reported. The study also treated obesity as a binary category, lacking the granularity to distinguish between different classes of obesity (e.g., Class I vs. Class III).

Conclusion

This research confirms that obesity is a primary driver of severe COVID-19 outcomes. These findings are essential for guiding clinical practice and future preventative strategies, reinforcing the need to prioritize individuals with obesity in vaccination and treatment protocols. The data provided serves as a robust foundation for future association studies focusing on the biological mechanisms of SARS-CoV-2 in the context of metabolic health.

Summary updated

Abstract

Abstract Background COVID-19 may differentially impact people with obesity. We aimed to describe and compare the demographics, comorbidities, and outcomes of obese patients with COVID-19 to those of non-obese patients with COVID-19, or obese patients with seasonal influenza. Methods We conducted a cohort study based on outpatient/inpatient care, and claims data from January to June 2020 from the US, Spain, and the UK. We used six databases standardized to the OMOP common data model. We defined two cohorts of patients diagnosed and/or hospitalized with COVID-19. We created corresponding cohorts for patients with influenza in 2017-2018. We followed patients from index date to 30 days or death. We report the frequency of socio-demographics, prior comorbidities, and 30-days outcomes (hospitalization, events, and death) by obesity status. Findings We included 627 044 COVID-19 (US: 502 650, Spain: 122 058, UK: 2336) and 4 549 568 influenza (US: 4 431 801, Spain: 115 224, UK: 2543) patients. The prevalence of obesity was higher among hospitalized COVID-19 (range: 38% to 54%) than diagnosed COVID-19 (30% to 47%), or diagnosed (15% to 47%) or hospitalized (27% to 48%) influenza patients. Obese hospitalized COVID-19 patients were more often female and younger than non-obese COVID-19 patients or obese influenza patients. Obese COVID-19 patients were more likely to have prior comorbidities, present with cardiovascular and respiratory events during hospitalization, require intensive services, or die compared to non-obese COVID-19 patients. Obese COVID-19 patients were more likely to require intensive services or die compared to obese influenza patients, despite presenting with fewer comorbidities. Interpretation We show that obesity is more common amongst COVID-19 than influenza patients, and that obese patients present with more severe forms of COVID-19 with higher hospitalization, intensive services, and fatality than non-obese patients. These data are instrumental for guiding preventive strategies of COVID-19 infection and complications. Funding The European Health Data &amp; Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research &amp; Development, and IQVIA. The University of Oxford received funding related to this work from the Bill &amp; Melinda Gates Foundation (Investment ID INV-016201 and INV-019257). APU has received funding from the Medical Research Council (MRC) [MR/K501256/1, MR/N013468/1] and Fundación Alfonso Martín Escudero (FAME) (APU). VINCI [VA HSR RES 13-457] (SLD, MEM, KEL). JCEL has received funding from the Medical Research Council (MR/K501256/1) and Versus Arthritis (21605). No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, Department of Veterans Affairs or the United States Government, NHS, or the Department of Health, England. Research in context Evidence before this study Previous evidence suggests that obese individuals are a high risk population for COVID-19 infection and complications. We searched PubMed for articles published from December 2019 until June 2020, using terms referring to SARS-CoV-2 or COVID-19 combined with terms for obesity. Few studies reported obesity and most of them were limited by small sample sizes and restricted to hospitalized patients. Further, they used different definitions for obesity (i.e. some reported together overweight and obesity, others only reported obesity with BMI&gt;40kg/m 2 ). To date, no study has provided detailed information on the characteristics of obese COVID-19 patients, such as the prevalence of comorbidities or COVID-19 related outcomes. In addition, despite the fact that COVID-19 has been often compared to seasonal influenza, there are no studies assessing whether obese patients with COVID-19 differ from obese patients with seasonal influenza. Added value of this study We report the largest cohort of obese patients with COVID-19 and provide information on more than 29 000 aggregate characteristics publicly available. Our findings were consistent across the participating databases and countries. We found that the prevalence of obesity is higher among COVID-19 compared to seasonal influenza patients. Obese patients with COVID-19 are more commonly female and have worse outcomes than non-obese patients. Further, they have worse outcomes than obese patients with influenza, despite presenting with fewer comorbidities. Implications of all the available evidence Our results show that individuals with obesity present more comorbidities and worse outcomes for COVID-19 than non-obese patients. These findings may be useful in guiding clinical practice and future preventative strategies for obese individuals, as well as provide useful data to support subsequent association studies focussed on obesity and COVID-19.
BibTeX
@misc{recalde2020characteristics,
  author = {Martina Recalde and Elena Roel and Andrea Pistillo and Anthony G. Sena and Albert Prats‐Uribe and Waheed‐Ul‐Rahman Ahmed and Heba Alghoul and Thamir M. Alshammari and Osaid Alser and Carlos Areia and Edward Burn and Paula Casajust and Dalia Dawoud and Scott L. DuVall and Thomas Falconer and Sergio Fernández‐Bertolín and Asieh Golozar and Mengchun Gong and Lana Yin Hui Lai and Jennifer C. E. Lane and Kristine E. Lynch and Michael E. Matheny and Paras Mehta and Daniel R. Morales and Karthik Natarjan and Fredrik Nyberg and Jose Posada and Christian Reich and Lisa M. Schilling and Karishma Shah and Nigam H. Shah and Vignesh Subbian and Lin Zhang and Hong Zhu and Patrick Ryan and Daniel Prieto‐Alhambra and Kristin Kostka and Talita Duarte‐Salles},
  title = {{Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom}},
  year = {2020},
  doi = {10.1101/2020.09.02.20185173},
  howpublished = {medRxiv},
}
Figure